Landos Biopharma, Inc. Common Stock
LABP
LABP was delisted on the 23rd of May, 2024.
35 hedge funds and large institutions have $331M invested in Landos Biopharma, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
27% more capital invested
Capital invested by funds: $261M → $331M (+$69.7M)
6% more funds holding
Funds holding: 33 → 35 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
33% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$6.57M |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$244K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$236K |
| 4 |
State Street
Boston,
Massachusetts
|
+$197K |
| 5 |
Renaissance Technologies
New York
|
+$141K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$5.16M |
| 2 |
JP Morgan Chase
New York
|
-$842K |
| 3 |
BlackRock
New York
|
-$784K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$354K |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$206K |
LABP Hedge Fund Activity: Q3 2021 in Review
35 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Landos Biopharma, Inc. Common Stock (LABP) for Q3 2021, worth a combined $331M — up 27% from $261M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new LABP positions and 3 closed out — a net gain of 2 holders — while 10 added to existing stakes and 15 trimmed.
The largest buyer was Logos Global Management, adding an estimated $6.57M. The largest seller was OrbiMed, cutting an estimated $5.16M.
- 35 institutional investors held Landos Biopharma, Inc. Common Stock (LABP) as of Q3 2021, up from 33 in Q2 2021.
- Funds reported $331M of Landos Biopharma, Inc. Common Stock stock for Q3 2021, up 27% quarter-over-quarter.
- 5 funds opened new Landos Biopharma, Inc. Common Stock positions in Q3 2021 and 3 closed out, a net change of +2 holders.
- The largest Landos Biopharma, Inc. Common Stock buyer in Q3 2021 was Logos Global Management, an estimated $6.57M added.
- The largest Landos Biopharma, Inc. Common Stock seller in Q3 2021 was OrbiMed, an estimated $5.16M sold.
Based on aggregated 13F filings for Q3 2021.